Salud financiera de hoja de balance de Clinuvel Pharmaceuticals

Salud financiera controles de criterios 6/6

Clinuvel Pharmaceuticals tiene un patrimonio de accionistas total de A$203.0M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$231.1M y A$28.1M respectivamente. El BAIT de Clinuvel Pharmaceuticals es de A$48.6M, por lo que su ratio de cobertura de intereses es de -16.9. Tiene efectivo e inversiones a corto plazo que ascienden a A$183.9M.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	-16.9x
Efectivo	AU$183.87m
Patrimonio	AU$203.01m
Total pasivo	AU$28.11m
Activos totales	AU$231.12m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$222.1M) de CUV superan a sus pasivos a corto plazo (A$25.2M).

Pasivo a largo plazo: Los activos a corto plazo de CUV (A$222.1M) superan a sus pasivos a largo plazo (A$2.9M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: CUV está libre de deudas.

Reducción de la deuda: CUV no ha tenido ninguna deuda en los últimos 5 años.

Cobertura de la deuda: CUV no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: CUV no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.

Salud financiera de hoja de balance de Clinuvel Pharmaceuticals

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Dividend of AU$0.05 announced

Full year 2024 earnings released: EPS: AU$0.71 (vs AU$0.62 in FY 2023)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Investor sentiment deteriorates as stock falls 17%

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings released: EPS: AU$0.62 (vs AU$0.42 in FY 2022)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

Investor sentiment deteriorates as stock falls 19%

Now 22% undervalued

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

No independent directors

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings released: EPS: AU$0.42 (vs AU$0.50 in FY 2021)

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Investor sentiment improved over the past week

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Investor sentiment improved over the past week

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 28% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

CEO, MD & Director recently sold AU$2.6m worth of stock

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021

Investor sentiment improved over the past week

Revenue misses expectations

First half 2021 earnings released: EPS AU$0.13 (vs AU$0.013 in 1H 2020)

New 90-day low: AU$20.11

Clinuvel Pharmaceuticals Limited to Report First Half, 2021 Results on Feb 26, 2021

Clinuvel Pharmaceuticals Limited Announces First Patient Dosed in SCENESSE DNA Repair Program

New 90-day low - AU$21.04

Earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera